[{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Pandion Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ligand Enters into OmniAb\u00ae Platform License Agreement with Pandion Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Ligand Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ligand Pharmaceuticals \/ Pandion Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Ligand Pharmaceuticals \/ Pandion Therapeutics"},{"orgOrder":0,"company":"Atomwise","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","amount":"$1,080.0 million","upfrontCash":"Undisclosed","newsHeadline":"Atomwise, Bridge Biotherapeutics pen $1B deal for AI-devised molecules","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Pellino protein","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Atomwise","amount2":1.0800000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.0800000000000001,"dosageForm":"","sponsorNew":"Atomwise \/ Bridge Biotherapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Atomwise \/ Bridge Biotherapeutics"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Galapagos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Galapagos and Ryvu Announce Research Collaboration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"POLAND","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Ryvu Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ Galapagos NV","highestDevelopmentStatusID":"2","companyTruncated":"Ryvu Therapeutics \/ Galapagos NV"},{"orgOrder":0,"company":"Curadev Pharma Private Limited","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$270.4 million ","upfrontCash":"Undisclosed","newsHeadline":"Bayer and Curadev Sign Research Collaboration and License Agreement to Develop novel STING Antagonists Across Indications","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Curadev Pharma Private Limited","amount2":0.27000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Curadev Pharma Private Limited \/ Bayer","highestDevelopmentStatusID":"2","companyTruncated":"Curadev Pharma Private Limited \/ Bayer"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ventus Uncloaks with $60M to Target the Innate immune System","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"IL-1B","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Ventus Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Ventus Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Ventus Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Iontas","sponsor":"Inotrem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IONTAS Announces a New Collaboration to Identify Novel Immunotherapy Targets with Inotrem","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Antibodies","moa":"TREM-1","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Iontas","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iontas \/ Inotrem","highestDevelopmentStatusID":"2","companyTruncated":"Iontas \/ Inotrem"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"S.R. One","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"SR One fuels HotSpot's $65M B round to fund allosteric R&D","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"PKC theta","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"HotSpot Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"HotSpot Therapeutics \/ S.R. One","highestDevelopmentStatusID":"2","companyTruncated":"HotSpot Therapeutics \/ S.R. One"},{"orgOrder":0,"company":"Dyno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyno Therapeutics Announces Presentations at 2020 American Society of Gene and Cell Therapy Conference","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Synthetic AAV capsids Proteins","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Dyno Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Dyno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Quench Bio","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Quench Bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Quench Bio \/ RA Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Quench Bio \/ RA Capital Management"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"JPEO-CBRND","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"SIGA Technologies Announces Department of Defense Increases Funding to Develop Post-Exposure Prophylactic Indication for TPOXX\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"SIGA Technologies","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"SIGA Technologies \/ JPEO-CBRND","highestDevelopmentStatusID":"2","companyTruncated":"SIGA Technologies \/ JPEO-CBRND"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$414.0 million","upfrontCash":"Undisclosed","newsHeadline":"SIGA Announces Deliveries of Oral TPOXX\u00ae to HHS Valued at Approximately $32 Million","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"SIGA Technologies","amount2":0.40999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"Oral","sponsorNew":"SIGA Technologies \/ BARDA","highestDevelopmentStatusID":"2","companyTruncated":"SIGA Technologies \/ BARDA"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Hemogenyx Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hemogenyx Pharmaceuticals PLC Announces Development Agreement - Autoimmune Disease Treatments","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hemogenyx Pharmaceuticals \/ Hemogenyx Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Hemogenyx Pharmaceuticals \/ Hemogenyx Pharmaceuticals"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$55.0 million","newsHeadline":"Dragonfly Therapeutics Announces Collaboration with BMS to Develop Novel Therapeutic Candidates for M.S and Neuro-inflammation Targets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"NK cell Engager Therapies","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Dragonfly Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dragonfly Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Dragonfly Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"HitGen","sponsor":"Morphic Therapeutic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen and Morphic Extend Drug Discovery Research Collaboration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"HitGen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HitGen \/ Morphic Therapeutic","highestDevelopmentStatusID":"2","companyTruncated":"HitGen \/ Morphic Therapeutic"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabis derived compounds","moa":"A3AR","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Can-Fite BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,040.0 million","upfrontCash":"$40.0 million","newsHeadline":"Jnana Therapeutics Enters Collaboration with Roche to Discover Novel Medicines that Target Key Regulators of Cellular Metabolism","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Solute carrier","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Jnana Therapeutics","amount2":1.04,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.04,"dosageForm":"","sponsorNew":"Jnana Therapeutics \/ Roche","highestDevelopmentStatusID":"2","companyTruncated":"Jnana Therapeutics \/ Roche"},{"orgOrder":0,"company":"Rutgers University","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DuPont Nutrition & Biosciences Announces Research Collaboration with Rutgers University","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Gut-Microbiome","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Rutgers University","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rutgers University \/ DuPont","highestDevelopmentStatusID":"2","companyTruncated":"Rutgers University \/ DuPont"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$409.0 million","upfrontCash":"$32.0 million","newsHeadline":"Sosei Heptares and AbbVie Announce New Discovery Collaboration Targeting Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0.40999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Sosei Heptares \/ AbbVie","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ AbbVie"},{"orgOrder":0,"company":"Lead Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$328.2 million","upfrontCash":"$12.1 million","newsHeadline":"Lead Pharma Inks Research Collaboration and License Agreement with Roche to Develop Oral Small Molecules for Immune Mediated Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Lead Pharma","amount2":0.33000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"Lead Pharma \/ Roche","highestDevelopmentStatusID":"2","companyTruncated":"Lead Pharma \/ Roche"},{"orgOrder":0,"company":"University of Glasgow","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$6.4 million","upfrontCash":"Undisclosed","newsHeadline":"UOFG Announces Research Collaboration with Lilly to Discover Potential New Drug Targets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"University of Glasgow","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"University of Glasgow \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"University of Glasgow \/ Eli Lilly"},{"orgOrder":0,"company":"Iontas","sponsor":"Quellis Biosciences Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IONTAS and FairJourney Biologics Enter Antibody Discovery Agreement With Quell Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Engineered Treg cell therapy product","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Iontas","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iontas \/ Quell","highestDevelopmentStatusID":"2","companyTruncated":"Iontas \/ Quell"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"BVF Partners L.P","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ventus Therapeutics Closes $100 Million Series B Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"NLRP3","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Ventus Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ventus Therapeutics \/ BVF Partners L.P","highestDevelopmentStatusID":"2","companyTruncated":"Ventus Therapeutics \/ BVF Partners L.P"},{"orgOrder":0,"company":"Stanford Medical","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi Partners with Stanford on Immunology research","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Stanford Medical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stanford Medical \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Stanford Medical \/ Sanofi"},{"orgOrder":0,"company":"TetraGenetics","sponsor":"AbCellera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"TetraGenetics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TetraGenetics \/ AbCellera","highestDevelopmentStatusID":"2","companyTruncated":"TetraGenetics \/ AbCellera"},{"orgOrder":0,"company":"Lycia Therapeutics","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Series B Financing","leadProduct":"LYTAC-based Therapeutics","moa":"Lysosomal targeting chimera","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Lycia Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Lycia Therapeutics \/ Redmile Group","highestDevelopmentStatusID":"2","companyTruncated":"Lycia Therapeutics \/ Redmile Group"},{"orgOrder":0,"company":"Mozart Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mozart Therapeutics Launches with $55 Million Series A Financing to Develop Disease Modifying Therapeutics for Autoimmune and Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"CD8 Treg Cell","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Mozart Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Mozart Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Mozart Therapeutics \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Bioqube Ventures","sponsor":"Metrion Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Metrion Biosciences and Bioqube Ventures Collaborate on Venture Creation Project to Identify Novel Ion Channel Inhibitors for Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Kv1.3 potassium ion channel","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Bioqube Ventures","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Bioqube Ventures \/ Metrion","highestDevelopmentStatusID":"2","companyTruncated":"Bioqube Ventures \/ Metrion"},{"orgOrder":0,"company":"Kynos Therapeutics","sponsor":"Epidarex Capital","pharmaFlowCategory":"D","amount":"$11.8 million","upfrontCash":"Undisclosed","newsHeadline":"Kynos Therapeutics Emerges from Stealth with \u00a39 Million Financing and Phase 1-ready KMO Inhibitor","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2022","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"KMO","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Kynos Therapeutics","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Kynos Therapeutics \/ Epidarex Capital","highestDevelopmentStatusID":"2","companyTruncated":"Kynos Therapeutics \/ Epidarex Capital"},{"orgOrder":0,"company":"Microba Life Sciences","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Microba Life Sciences and Ginkgo Bioworks Announce Partnership to Discover Novel Live Biotherapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Partnership","leadProduct":"Microbiome Based Product","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Microba Life Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Microba Life Sciences \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Microba Life Sciences \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Queensland University of Technology","sponsor":"Quoin Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Quoin Pharmaceuticals Enters Exclusive Research Agreement for Scleroderma Treatment with Australian University","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"VCAM-1","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Queensland University of Technology","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Queensland University of Technology \/ Quoin Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Queensland University of Technology \/ Quoin Pharmaceuticals"},{"orgOrder":0,"company":"Ermium Therapeutics","sponsor":"Kurma Partners","pharmaFlowCategory":"D","amount":"$12.8 million","upfrontCash":"Undisclosed","newsHeadline":"Ermium Therapeutics Extends Its Initial \u20ac6.3 M Funding to \u20ac12.3 M","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2022","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"CXCR4","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Ermium Therapeutics","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Ermium Therapeutics \/ Kurma Partners","highestDevelopmentStatusID":"2","companyTruncated":"Ermium Therapeutics \/ Kurma Partners"},{"orgOrder":0,"company":"NexImmune","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NexImmune Announces Research Collaboration with National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"T-Cell Therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NexImmune \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"2","companyTruncated":"NexImmune \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$335.0 million","upfrontCash":"$40.0 million","newsHeadline":"AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"HotSpot Therapeutics","amount2":0.34000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"HotSpot Therapeutics \/ AbbVie","highestDevelopmentStatusID":"2","companyTruncated":"HotSpot Therapeutics \/ AbbVie"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$409.0 million","upfrontCash":"$32.0 million","newsHeadline":"Sosei Heptares Receives $10 Million Milestone Payment in Discovery Collaboration with AbbVie Targeting Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0.40999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Sosei Heptares \/ AbbVie","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ AbbVie"},{"orgOrder":0,"company":"Monash University","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ono Pharmaceutical Enters Research Deal With Monash University","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Monash University","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monash University \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Monash University \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Avilar Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avilar Therapeutics Increases Financing to $75 Million to Advance Pipeline of Novel Extracellular Protein Degraders","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Avilar Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Avilar Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Avilar Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Aqilion","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"$1,025.0 million","upfrontCash":"$10.6 million","newsHeadline":"Aqilion Announces Pre-Clinical Licensing and Strategic Research Collaboration Agreement with Merck","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Aqilion","amount2":1.03,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.03,"dosageForm":"","sponsorNew":"Aqilion \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Aqilion \/ Merck"},{"orgOrder":0,"company":"Pragma Bio","sponsor":"Viking Global","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pragma Bio Secures $10M From The Venture Collective, Merck Global Health Innovation Fund, Viking Global, and CJ Investments To Expand Its Proprietary Technology Platform To Discover Novel Medicines","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Pragma Bio","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Pragma Bio \/ Viking Global","highestDevelopmentStatusID":"2","companyTruncated":"Pragma Bio \/ Viking Global"},{"orgOrder":0,"company":"Sygnature Discovery","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daewoong Pharmaceutical and Sygnature Discovery Announce Drug Discovery Research Collaboration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Sygnature Discovery","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sygnature Discovery \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Sygnature Discovery \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience Enters into Third Collaboration with Astellas to Support Antibody Discovery for Immunotherapies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Astellas Pharma"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Kinnevik","pharmaFlowCategory":"D","amount":"$119.0 million","upfrontCash":"Undisclosed","newsHeadline":"Enveda Biosciences Announces Oversubscribed Series B1 Bringing Total Round to US$119 Million","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Enveda Bioscience","amount2":0.12,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.12,"dosageForm":"Aerosol (PMDI)","sponsorNew":"Enveda Bioscience \/ Kinnevik","highestDevelopmentStatusID":"2","companyTruncated":"Enveda Bioscience \/ Kinnevik"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$1,715.0 million","upfrontCash":"$35.0 million","newsHeadline":"Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Arcus Biosciences","amount2":1.72,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.72,"dosageForm":"","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Metaphore Biotechnologies","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Metaphore Biotechnologies","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Metaphore Biotechnologies \/ Flagship Pioneering","highestDevelopmentStatusID":"2","companyTruncated":"Metaphore Biotechnologies \/ Flagship Pioneering"},{"orgOrder":0,"company":"Empress Therapeutics","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Empress Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Empress Therapeutics \/ Flagship Pioneering","highestDevelopmentStatusID":"2","companyTruncated":"Empress Therapeutics \/ Flagship Pioneering"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Evozyne","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","amount":"$81.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evozyne Announces $81 Million Financing Round to Advance Generative AI for Therapeutic Discovery and Drug Development","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Evozyne","amount2":0.080000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Evozyne \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"2","companyTruncated":"Evozyne \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Atomwise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atomwise Announces Nomination of its First AI-Driven Development Candidate Focused on TYK2 Inhibition and Appoints Neely Mozaffarian, MD, PhD as Chief Medical Officer","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Atomwise","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atomwise \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Atomwise \/ Not Applicable"},{"orgOrder":0,"company":"BioMap","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$10.0 million","newsHeadline":"BioMap Establishes a Strategic Collaboration with Sanofi to Co-Develop AI Modules to Accelerate Drug Discovery for Biotherapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"BioMap","amount2":1,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1,"dosageForm":"","sponsorNew":"BioMap \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"BioMap \/ Sanofi"},{"orgOrder":0,"company":"Immetas Therapeutics","sponsor":"GC Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immetas Therapeutics and GC Biopharma Announce Research Collaboration to Discover and Develop mRNA Therapeutics to Treat Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"mRNA Therapeutic","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Immetas Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immetas Therapeutics \/ GC Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Immetas Therapeutics \/ GC Biopharma"},{"orgOrder":0,"company":"Elektrofi","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$470.0 million","upfrontCash":"$20.0 million","newsHeadline":"Elektrofi and Lilly Enter Multi-Target Research Collaboration and License Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Elektrofi","amount2":0.46999999999999997,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.46999999999999997,"dosageForm":"","sponsorNew":"Elektrofi \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Elektrofi \/ Eli Lilly"},{"orgOrder":0,"company":"TRexBio","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TRexBio Announces a First Option Was Exercised by Partner under Immunology Discovery Collaboration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"TRexBio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TRexBio \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"2","companyTruncated":"TRexBio \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Odyssey Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Odyssey Therapeutics Announces Strategic Collaboration to Advance AI-Driven Small Molecule Drug Discovery","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Odyssey Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Odyssey Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Odyssey Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$2,577.0 million","upfrontCash":"$55.0 million","newsHeadline":"Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Nurix Therapeutics","amount2":2.5800000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":2.5800000000000001,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Nurix Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"DeepCure","sponsor":"IAG Capital Partners","pharmaFlowCategory":"D","amount":"$24.6 million","upfrontCash":"Undisclosed","newsHeadline":"DeepCure Closes $24M Funding Round Led by IAG Capital Partners","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Series A Financing","leadProduct":"Brd4","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"DeepCure","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"DeepCure \/ IAG Capital Partners","highestDevelopmentStatusID":"2","companyTruncated":"DeepCure \/ IAG Capital Partners"},{"orgOrder":0,"company":"Radar Therapeutics","sponsor":"NfX Bio","pharmaFlowCategory":"D","amount":"$13.4 million","upfrontCash":"Undisclosed","newsHeadline":"Radar Therapeutics Raises $13.4M in Seed Funding for Programmable Medicines","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"mRNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Radar Therapeutics","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Radar Therapeutics \/ NfX Bio","highestDevelopmentStatusID":"2","companyTruncated":"Radar Therapeutics \/ NfX Bio"},{"orgOrder":0,"company":"LogiX Biosciences","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Logix Biosciences Partners with Mayo Clinic for Allergy Relief and Infectious Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"LogiX Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LogiX Biosciences \/ Mayo Clinic","highestDevelopmentStatusID":"2","companyTruncated":"LogiX Biosciences \/ Mayo Clinic"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"PrecisionLife","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Sosei Group Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Group Corporation \/ PrecisionLife","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Group Corporation \/ PrecisionLife"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Details :
The funding will be used to support Jade's plans to develop targeted therapies for indications with high unmet need across inflammation and immunology.
Details :
AbCellera expanded its existing collaboration with Eli Lilly to discover therapeutic antibodies for programs in immunology, cardiovascular disease, and neuroscience.
Details :
The partnership aims to develop new generational & multi-specific antibodies to address the treatment of autoimmune diseases such as SLE and drive significant progress in the self-immune drug market.
Details :
AstraZeneca has added a novel target for systemic lupus erythematosus (SLE) to its discovery portfolio through its collaboration with BenevolentAI and by using its AI-drug discovery platform.
Details :
The agreement aims to advance development of therapeutics for allergy relief, mutating infectious diseases and antimicrobial resistance with Mayo Clinic’s research infrastructure.
Details :
The strategic R&D partnership for the auto-immune disorders with the potential to identify new drug targets for the treatment of complex, chronic conditions.
Details :
The financing will support advancement of Radar’s internal programs including, programmable genetic and mRNA-based therapeutics that use RNA sensors for autoimmune diseases.
Details :
The net proceeds will be used to further develop DeepCure’s cutting-edge technology for small molecule drug discovery, and to advance its immunology and inflammation pipeline towards clinical trials.
Details :
Nurix and Sanofi have agreed to extend the research period for the ongoing STAT6 degrader program, aimed at developing candidates for treating inflammation and autoimmune diseases.
Details :
The companies will jointly discover and optimize small molecule medicines against select therapeutic targets by combining their expertise in artificial intelligence, machine learning, computational chemistry and drug discovery to unlock difficult-to-drug...
Market Place
Reset All
